Dr. Richman's research focuses on chimeric antigen receptor (CAR) T cells targeting solid tumors with the goal of translating these findings to this unmet clinical need.
It was a pivotal moment that has turned into a new era for cancer immunotherapy. On April 17, 2012, Children's Hospital of Philadelphia researchers for the first time treated a pediatric patient with a cellular therapy that used her own reprogrammed immune cells, called T cells, to attack her aggressive form of blood cancer.
Super Bowl Sunday is right around the corner, and our biweekly installment of In the News is the perfect playing field for us to showcase the wide range of research projects that Children's Hospital of Philadelphia experts tackle. Huddle up!
Cookies for Kids’ Cancer, a nonprofit foundation dedicated to pediatric cancer research, uses the proceeds from its cookie sales and other fundraising events to provide grants to support the work of scientists at five of the nation’s leading pediatric cancer centers.
